Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
No safety concerns or dose limiting toxicities observedSCY-247 was able to achieve target exposures at doses lower than our first-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback